These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Acute stent thrombosis of a bioresorbable vascular scaffold implanted for ST-segment elevation myocardial infarction. Miyazaki T; Panoulas VF; Sato K; Naganuma T; Latib A; Colombo A Int J Cardiol; 2014 Jun; 174(2):e72-4. PubMed ID: 24784914 [No Abstract] [Full Text] [Related]
46. Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts. Taniwaki M; Räber L; Magro M; Kalesan B; Onuma Y; Stefanini GG; van Domburg RT; Moschovitis A; Meier B; Jüni P; Serruys PW; Windecker S EuroIntervention; 2014; 9(12):1432-40. PubMed ID: 24064377 [TBL] [Abstract][Full Text] [Related]
47. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495 [TBL] [Abstract][Full Text] [Related]
49. Feasibility and efficacy of bioresorbable vascular scaffolds use for the treatment of in-stent restenosis and a bifurcation lesion in a heavily calcified diffusely diseased vessel. Naganuma T; Costopoulos C; Latib A; Sato K; Miyazaki T; Colombo A JACC Cardiovasc Interv; 2014 May; 7(5):e45-6. PubMed ID: 24746654 [No Abstract] [Full Text] [Related]
50. Bioresorbable vascular scaffolds in left main coronary artery disease. Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148 [TBL] [Abstract][Full Text] [Related]
51. First ad hoc bioresorbable vascular scaffold bench test: a glimpse into percutaneous bifurcation interventions. Sgueglia GA; D'Errico F; Gioffrè G; De Santis A; Gaspardone A Int J Cardiol; 2014 Apr; 172(3):604-6. PubMed ID: 24491860 [No Abstract] [Full Text] [Related]
52. Biodegradable polymer versus permanent polymer sirolimus-eluting stents in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Zhang F; Zheng Y; Qian J; Ge L; Huang D; Ma J; Yao K; Ge J Int J Cardiol; 2012 Jun; 158(1):118-20. PubMed ID: 22560946 [No Abstract] [Full Text] [Related]
53. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. Haude M; Lee SW; Worthley SG; Silber S; Verheye S; Erbs S; Rosli MA; Botelho R; Meredith I; Sim KH; Stella PR; Tan HC; Whitbourn R; Thambar S; Abizaid A; Koh TH; Den Heijer P; Parise H; Cristea E; Maehara A; Mehran R JACC Cardiovasc Interv; 2013 Apr; 6(4):334-43. PubMed ID: 23523459 [TBL] [Abstract][Full Text] [Related]
54. Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography. Tada T; Byrne RA; Schuster T; Cuni R; Kitabata H; Tiroch K; Dirninger A; Gratze F; Kaspar K; Zenker G; Joner M; Schömig A; Kastrati A Cardiovasc Revasc Med; 2013; 14(2):84-9. PubMed ID: 23352095 [TBL] [Abstract][Full Text] [Related]
55. [What is the place of bioresorbable vascular scaffolds in setting of ST-segment elevation myocardial infarction?]. Lattuca B; Schmutz L; Ledermann B; Cornillet L; Messner-Pellenc P; Leclercq F; Cayla G Ann Cardiol Angeiol (Paris); 2015 Dec; 64(6):499-504. PubMed ID: 26482633 [TBL] [Abstract][Full Text] [Related]
56. Comparison of outcomes after percutaneous coronary intervention for chronic total occlusion using everolimus- versus sirolimus- versus paclitaxel-eluting stents (from the Korean National Registry of Chronic Total Occlusion Intervention). Lee MH; Lee JM; Kang SH; Yoon CH; Jang Y; Yu CW; Park HS; Lee SH; Hur SH; Kim MH; Rha SW; Gwon HC; Chae IH; Kim HS Am J Cardiol; 2015 Jul; 116(2):195-203. PubMed ID: 26001819 [TBL] [Abstract][Full Text] [Related]
57. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). Kajiya T; Liang M; Sharma RK; Lee CH; Chan MY; Tay E; Chan KH; Tan HC; Low AF EuroIntervention; 2013 Aug; 9(4):501-4. PubMed ID: 23687101 [TBL] [Abstract][Full Text] [Related]
58. Impact on myocardial reperfusion using the M-Guard stent in primary percutaneous coronary intervention for ST-elevation myocardial infarction. Anthopoulos P; Alexanian I; Karabela G; Pappas L; Antonellis I; Salahas A; Polydorou A Int J Cardiol; 2014 Sep; 176(2):546-7. PubMed ID: 25074557 [No Abstract] [Full Text] [Related]
59. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859 [TBL] [Abstract][Full Text] [Related]
60. Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial). Stiermaier T; Heinz A; Schloma D; Kleinertz K; Dänschel W; Erbs S; Linke A; Boudriot E; Lauer B; Schuler G; Thiele H; Desch S Catheter Cardiovasc Interv; 2014 Feb; 83(3):418-24. PubMed ID: 23873579 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]